BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
October 04 2023 - 9:00AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, is pleased to announce a partnership with New York Cancer
& Blood Specialists (NYCBS), a group of leading community
cancer centers in the United States, to evaluate the Bria-IMT™
combination with a checkpoint inhibitor in its pivotal Phase 3
registration study in advanced breast cancer patients in New York.
“Cancer is complex. It takes a village to care
for a cancer patient. At NYCBS, our mission is to offer cancer
patients access to state-of-the-art treatments close to their
homes, families, and support networks at convenient locations
across Long Island, New York City, and Upstate New York,” stated
Dr. Jeffrey Vacirca, CEO of NYCBS. “We were impressed with the
survival data of the Bria-IMT™ regimen to date and look forward to
working with the BriaCell team to make these novel therapeutics
available to our patients.”
“We are very honored to work with the team of
medical and health specialists at one of the nation’s leading
cancer centers,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief
Medical Officer. “Their insights and dedication to excellent
patient care will be of utmost importance to us in our upcoming
pivotal registration study.”
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
About New York Cancer & Blood
Specialists (NYCBS)
New York Cancer & Blood Specialists (NYCBS)
is a leading oncology practice in the New York Metropolitan area
committed to providing world-class, patient-centered affordable
care to patients with cancer and blood disorders in their own
communities, close to family and friends. NYCBS has more than 30
locations and 35 hospital affiliations throughout Nassau and
Suffolk counties, in the Bronx, Manhattan, Queens, Staten Island,
and Brooklyn. We offer a multidisciplinary and comprehensive
approach to care that utilizes the most advanced imaging,
state-of-the-art therapies, cutting-edge clinical trials, on-site
pharmacies, and an in-house laboratory with a full range of
pathology services. Advocating for and ensuring the health and
well-being of our patients is and always will be our top priority.
For more information, visit www.nycancer.com.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including in relation to the ability of the medical
advisory board to assist the Company with its registration studies,
developing novel immunotherapies and achieving desirable outcomes
for advanced breast cancer patients, are based on BriaCell’s
current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully under the heading
“Risks and Uncertainties” in the Company's most recent Management’s
Discussion and Analysis, under the heading "Risk Factors" in the
Company's most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (TSX:BCT)
Historical Stock Chart
From Sep 2024 to Oct 2024
BriaCell Therapeutics (TSX:BCT)
Historical Stock Chart
From Oct 2023 to Oct 2024